Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Vaccine maker Valneva loss narrows on lower investment

Published by Wanda Rich

Posted on May 5, 2022

Featured image for article about Top Stories

(Reuters) -French vaccine maker Valneva on Thursday reported a narrower quarterly loss helped by a fall in costs from development of its chikungunya vaccine and lower investment in research and development of its COVID-19 vaccine candidate.

It posted a loss of 18.4 million euros ($19.53 million) in adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) for the three months ended March 31, after a loss of 28.3 million a year earlier.

Revenue of 21.8 million euros ($23.13 million) was down 5.9%.

Research and development investment amounted to 20.7 million euros ($21.97 million) in the first quarter, down 25% from a year earlier.

Progress in its chikungunya vaccine program meant lower clinical trial costs while it also spent less on its COVID-19 vaccine candidate VLA2001, the company said.

The quarter also marked the first shipments of VLA2001, to Bahrain, taking COVID-19 vaccine sales to 3.8 million euros ($4.03 million).

Regarding VLA2001, which Britain approved in April, the company said it had provided responses to questions from the European Medicines Agency. The agency had asked for more data on the vaccine at the end of April.

Valneva confirmed its financial guidance for the year, for which it expects revenue of 430 million to 590 million euros, though it noted that “the distribution of total revenues by revenue category may differ from the figures announced”.

In February, it had guided for 350 to 500 million euros in sales of the VLA2001 vaccine for the year.

($1 = 0.9423 euros)

(Reporting by Valentine Baldassari; editing by Clarence Fernandez and Jason Neely)